There’s much more to the deal than just a $3b takeover offer; Merck stood to gain through milestones and royalties anyway.
I’m unsure of the details but see below:
Under the terms of the license agreement, Merck KGaA will receive an upfront payment as well as a minority equity stake in MoonLake Immunotherapeutics. Merck KGaA is eligible for potential development and commercial milestone payments as well as industry-standard royalties on net sales.
There’s much more to the deal than just a $3b takeover offer;...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.05 |
Change
-0.050(0.38%) |
Mkt cap ! $1.597B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $3.552M | 271.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 641 | $13.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.06 | 2156 | 7 |
View Market Depth
| Last trade - 15.32pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |